Phathom Pharmaceuticals, Inc. Ending Cash

Ending Cash of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Ending Cash growth rates and interactive chart.


Highlights and Quick Summary

  • Ending Cash for the quarter ending September 29, 2021 was $14.9 Million (a -152.81% decrease compared to previous quarter)
  • Year-over-year quarterly Ending Cash decreased by -75.55%
  • Annual Ending Cash for 2020 was $287 Million (a 17.94% increase from previous year)
  • Annual Ending Cash for 2019 was $244 Million (a 27632.08% increase from previous year)
  • Twelve month Ending Cash ending September 29, 2021 was $286 Million (a 14.35% increase compared to previous quarter)
  • Twelve month trailing Ending Cash decreased by -0.61% year-over-year
Trailing Ending Cash for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$286 Million $250 Million $269 Million $287 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Ending Cash of Phathom Pharmaceuticals, Inc.

Most recent Ending Cashof PHAT including historical data for past 10 years.

Interactive Chart of Ending Cash of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Ending Cash for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $14.95 $-28.31 $237.97
2020 $61.14 $-20.91 $-9.4 $256.67 $287.5
2019 $169.28 $-8.43 $82.85 $0.07 $243.77
2018 $0.75 $0.13 $0.88

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.